Call: 954-398-4474

Wegovy Adherence Rates in Recent Weight-Loss Drug Study

Wegovy Adherence Rates in Recent Weight-Loss Drug Study

Wegovy’s Adherence Triumph

A recent study’s findings shed light on the encouraging trend of patients. Wegovy Adherence Rates compared to other established weight-loss medications. Published in the journal Obesity, this cohort study, using electronic health records and insurance claims data, analyzed adults with a BMI ≥30 kg/m2 in Ohio and Florida who were prescribed anti-obesity medication (AOM) between 2015 and 2022.

Tip: Please fill out the form if you or a friend would like more information on blood glucose monitors.

Insights from Obesity Medication Study

The study revealed a striking discrepancy in adherence rates among different weight-loss drugs. After one year, an impressive 40% of patients on Wegovy continued their medication regimen, while the rates for older obesity medications lingered significantly lower, with only 19% of patients still adhering to the drugs at the 12-month mark.

Comparing Wegovy Adherence Rates

Contrastingly, patients on Orexigen Therapeutics’ Contrave and Vivus’ Qsymia demonstrated notably lower Wegovy adherence rates, with only 13% and minimal numbers continuing their prescriptions, respectively. Similarly, no patients persisted with Orlistat by the end of the 12-month period.

Weight Loss Impact on Adherence

The research also established a direct correlation between greater weight loss results at six months and sustained adherence at one year. Wegovy’s effectiveness for most individuals appears to contribute to its higher adherence rates. Furthermore, adherence varied based on the patients’ insurance carriers, particularly among those with private insurance.

Must Read CGMs in noncritical care hospitals optimizes glycemic control

Continuous Treatment for Obesity

Recognizing obesity as a chronic condition requiring ongoing treatment, the study highlights the need for continued medication intake to maintain benefits. Moreover, an accompanying opinion piece underscores the limited efficacy of behavioral approaches in achieving lasting weight loss for a majority of patients, emphasizing the significance of pharmaceutical interventions.

Pharmaceutical Innovations in Obesity

The surge in popularity of Novo Nordisk’s GLP-1 agonist Wegovy is evident, with third-quarter 2023 sales marking an exceptional 700% growth, accumulating approximately $3.1 billion in revenue for the initial nine months of 2023.

Also, read about Tandem Diabetes Care Introduces Dexcom G7 Integration for Insulin Pump Users

Market Impact and Surge of Wegovy

While Wegovy stands out, Eli Lilly’s recently approved tirzepatide, marketed as Zepbound, has also made waves in the market. Real-world analysis revealed tirzepatide’s superior weight loss compared to Wegovy, showcasing its potential in weight management.

Read Guide about Wegovy Dosage Guide: The Best Way For Weight Loss

Tirzepatide vs. Wegovy: Market Competition

However, Pfizer faced setbacks as it announced discontinuation of its twice-daily weight loss pill due to intolerable side effects experienced by patients in a mid-stage study, leading to discontinuation rates exceeding 50%. Nonetheless, Pfizer persists in exploring a once-daily version, danuglipron, with a pharmacokinetic study slated for the first half of 2024, intending to shape its future endeavors in the field.